{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4","value":"52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"To explore the activity of ZD1839 with chemotherapy and hyperfractionated radiation using 1-year survival","groups":[{"description":"Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"5-FU, Cisplatin, Radiation and Iressa"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 1 year after start of treatment","title":"Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival","type":"PRIMARY","unitOfMeasure":"participants"}